The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study
Open accessAbstract
SUMMARY Background: Ivacaftor is generally safe and effective in patients 2 years and older with cystic fibrosis (CF) and specific CFTR mutations. We evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), and exploratory efficacy of ivacaftor in children aged 12 to <24 months. Methods: This phase 3, single-arm, two-part, multicenter, multinational study (ARRIVAL) enrolled children 12 to <24 months with a confirmed diagnosis of CF and a CFTR gating mutation on at least one allele. Children received oral ivacaftor 50 mg (weight 7 to <14 kg) or 75 mg (weight ≥14 to <25 kg) every 12 hours for 4 days in part A (to assess short-term safety and PK) and 24 weeks in part B (to assess safety and PD and explore efficacy). Primary endpoints were PK (part A) and safety (A and B); analyses included all children who received ≥1 dose of ivacaftor. Secondary endpoints were PK and absolute change from baseline at week 24 in sweat chloride. Tertiary endpoints included absolute change from baseline at week 24 in growth parameters and markers of pancreatic function. Safety analyses in parts A and B were performed on all children dosed; PD and efficacy analyses in part B were performed on all children enrolled and dosed. Final data for children aged 12 to <24 months were collected from August 2016 to November 2017; ARRIVAL is ongoing for those aged <12 months. This study is registered with ClinicalTrials.gov, number NCT02725567. Findings: Seven children enrolled in part A, all of whom completed the 4-day treatment period and one of whom enrolled in part B. Nineteen children enrolled in part B, 18 of whom completed the 24-week treatment period. All patients received at least one dose of ivacaftor. PK results suggested that ivacaftor exposures were similar to those reported in older children and adults. Most adverse events (AEs) were typical for children with CF. The most common AE in part B was cough (in 14 [73·7%] of 19 children). Two children had four serious AEs; one (constipation) was considered to be possibly related to ivacaftor. Five (27·8%) of 18 children had transaminase elevations >3 × upper limit of normal (ULN) and remained on ivacaftor. Of these, two children had transaminase elevations >8 × ULN; both had concurrent infections and successfully resumed treatment after interruption. No children discontinued because of AEs or any safety findings. At week 24, mean (standard deviation) absolute change from baseline in sweat chloride was −73·5 (17·5) mmol/L. Growth parameters were normal at baseline and were generally maintained during treatment. There was an increase in fecal elastase-1 and a decrease in immunoreactive trypsinogen (IRT). Mean serum lipase and amylase were elevated at baseline and rapidly decreased with ivacaftor Interpretation: Ivacaftor at doses of 50 mg or 75 mg every 12 hours was generally safe and well tolerated in children 12 to <24 months with CF and a CFTR gating mutation for up to 24 weeks. Substantial improvements were observed in sweat chloride, and growth measures were generally well maintained. Reductions in lipase and amylase, a new observation, along with improvements in fecal elastase-1 and IRT, suggest ivacaftor could potentially preserve pancreatic function if initiated early in life. Funding: Vertex Pharmaceuticals Incorporated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Webb, A. K. (2006) · Cited by 4,369
Update on Key Emerging Challenges in Cystic Fibrosis
Jennings, M. T., Riekert, K. A., & Boyle, M. P. (2014) · Medical Principles and Practice · doi:10.1159/000357646 · Cited by 3,648
Nährlich, L., Mainz, J. G., Adams, C., Engel, C., Herrmann, G., Icheva, V., Lauer, J., Deppisch, C., Wirth, A., Unger, K., et al. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350071 · Cited by 2,525
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105185 · Cited by 2,195
Self-citationPractice guidelines in acute pancreatitis
Banks, P. A., Freeman, M. L., & the Practice Parameters Committee of the American College of Gastroenterology (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00856.x · Cited by 2,050
O'Sullivan, B. P., & Freedman, S. D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60327-5 · Cited by 1,320
Early pulmonary inflammation in infants with cystic fibrosis.
Khan, T. Z., Wagener, J. S., Bost, T., Martinez, J., Accurso, F. J., & Riches, D. W. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.4.7697234 · Cited by 1,263
Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation
Farrell, P. M., White, T. B., Ren, C. L., Hempstead, S. E., Accurso, F., Derichs, N., Howenstine, M., McColley, S. A., Rock, M., Rosenfeld, M., et al. (2017) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2016.09.064 · Cited by 953
Self-citationRisk Factors for Bronchiectasis in Children with Cystic Fibrosis
Sly, P. D., Gangell, C. L., Chen, L., Ware, R. S., Ranganathan, S., Mott, L. S., Murray, C. P., & Stick, S. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301725 · Cited by 595
Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
Rowe, S. M., Daines, C., Ringshausen, F. C., Kerem, E., Wilson, J., Tullis, E., Nair, N., Simard, C., Han, L., Ingenito, E. P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709847 · Cited by 522
Self-citation
Cited by
The future of cystic fibrosis care: a global perspective
Bell, S. C., Mall, M. A., Gutierrez, H., Macek, M., Madge, S., Davies, J. C., Burgel, P.-R., Tullis, E., Castaños, C., Castellani, C., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30337-6 · Cited by 974
Self-citationCFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine
Lopes-Pacheco, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01662 · Cited by 535
Cystic fibrosis in the year 2020: A disease with a new face
De Boeck, K. (2020) · Acta Paediatrica · doi:10.1111/apa.15155 · Cited by 332
Ong, T., & Ramsey, B. W. (2023) · JAMA · doi:10.1001/jama.2023.8120 · Cited by 315
CFTR modulator therapy: Transforming the landscape of clinical care in cystic fibrosis
Taylor-Cousar, J. L., Robinson, P. D., Shteinberg, M., & Downey, D. G. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01609-4 · Cited by 173
Self-citation
Metadata
- Authors
- Rosenfeld, M., Wainwright, C. E., Higgins, M., Wang, L. T., McKee, C., Campbell, D., Tian, S., Schneider, J., Cunningham, S., Davies, J. C., Rosenfeld, M., Wainwright, C. E., Higgins, M., Wang, L. T., McKee, C., Campbell, D., Tian, S., Schneider, J., Cunningham, S., Davies, J. C., Harris, W., Mogayzel, P., McCoy, K., Milla, C., Rubenstein, R., Walker, S., Black, P., Montgomery, G., McColley, S., Hiatt, P., Sawicki, G., Rock, M., Aurora, P., Ratjen, F., Maitra, A., Ives, A., Gaillard, E., McNalley, P., Selvadurai, H., & Robinson, P.
- Venue
- The Lancet Respiratory Medicine
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 6
- Issue
- 7
- Pages
- 545-553
- ISSN
- 2213-2600 (ISSN-L)
- OpenAlex
- W2805157317
- Cited by
- 273
- References
- 22
- FWCI
- 20.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. https://app.cochat.ai/papers/10.1016/s2213-2600(18)30202-9
- The paper
- Rosenfeld, M., Wainwright, C. E., Higgins, M., Wang, L. T., McKee, C., Campbell, D., Tian, S., Schneider, J., Cunningham, S., Davies, J. C., Rosenfeld, M., Wainwright, C. E., Higgins, M., Wang, L. T., McKee, C., Campbell, D., Tian, S., Schneider, J., Cunningham, S., . . . Robinson, P. (2018). Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(18)30202-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.